Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Caribou Biosciences (NASDAQ:CRBU) vary from bullish to somewhat bullish, with 3 out of 4 analysts giving a bullish rating. The average 12-month price target has dropped by 26.79% to $10.25. The company's financials show a decline in revenue and a high net margin, but strong ROE and ROA. Debt management is also favorable.
August 14, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Caribou Biosciences (NASDAQ:CRBU) has received mostly bullish ratings from analysts, but the average 12-month price target has dropped by 26.79% to $10.25. The company's financials show a decline in revenue but strong ROE and ROA.
The mixed analyst ratings and significant drop in the average price target suggest uncertainty in the stock's short-term performance. While the financials show strong ROE and ROA, the decline in revenue is a concern. This results in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100